Quarterly report [Sections 13 or 15(d)]

OVERVIEW

v3.26.3
OVERVIEW
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
OVERVIEW

1. OVERVIEW

 

Nature of Business

 

Interpace Biosciences, Inc. (“Interpace” or the “Company”) is a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer from clinical features. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management.

 

Reverse stock split

 

On August 27, 2026, the Company effected a one-for-five reverse split of its issued and outstanding shares of Common Stock. All share and per share amounts in prior periods have been retroactively adjusted to reflect the reverse stock split.